(Q33964349)

30 July 2017

1 reference

title

Dysthymia: a review of pharmacological and behavioral factors (English)

1 reference

30 July 2017

Griffiths J

1

1 reference

30 July 2017

Ravindran AV

series ordinal

2

1 reference

30 July 2017

Merali Z

series ordinal

3

1 reference

30 July 2017

Anisman H

series ordinal

4

1 reference

30 July 2017

language of work or name

English

0 references

publication date

1 May 2000

1 reference

30 July 2017

1 reference

30 July 2017

5

1 reference

30 July 2017

242-261

1 reference

30 July 2017

3

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.mp.4000697

30 July 2017

0 references

cites work

Biological studies of dysthymia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

Symptomatology in dysthymic and major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

Dysthymic disorder: psychopathology of proposed chronic depressive subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

Differential diagnosis of chronic depressive disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

The de facto US mental and addictive disorders service system. Epidemiologic catchment area prospective 1-year prevalence rates of disorders and services.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

One-month prevalence of mental disorders in the United States. Based on five Epidemiologic Catchment Area sites.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

Depressive disorders in childhood. I. A longitudinal prospective study of characteristics and recovery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

Pharmacotherapy of dysthymic and chronic depressive disorders: overview with focus on moclobemide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

Psychotherapy of dysthymia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

Treatment of primary dysthymia with group cognitive therapy and pharmacotherapy: clinical symptoms and functional impairments

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

"Double depression": superimposition of acute depressive episodes on chronic depressive disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

The epidemiology of dysthymia in five communities: rates, risks, comorbidity, and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

Depression and panic attacks: the significance of overlap as reflected in follow-up and family study data

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

Prevalence and comorbidity of dysthymic disorder among psychiatric outpatients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

The subaffective-character spectrum subtyping distinction in primary early-onset dysthymia: a clinical and family study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

Personality disorders in dysthymia and major depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

The comorbidity of alcohol dependence and affective disorders: treatment implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

Substance use and abuse among patients with comorbid dysthymia and substance disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

The impact of stressors on immune and central neurotransmitter activity: bidirectional communication.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

The early--late onset distinction in DSM-III-R dysthymia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

A critical discussion of DSM-III dysthymic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

Early-onset dysthymia and personality disturbance among patients in a primary care setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

Primary early-onset dysthymia: Comparison with primary nonbipolar nonchronic major depression on demographic, clinical, familial, personality, and socioenvironmental characteristics and short-term outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

Dysthymia: clinical picture, extent of overlap with chronic fatigue syndrome, neuropharmacological considerations, and new therapeutic vistas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

Psychiatric disorders and medical care utilization among people in the general population who report fatigue

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

Psychiatric disorders in patients with fibromyalgia. A multicenter investigation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

Psychological and psychiatric aspects of fibromyalgia syndrome (FMS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

Interleukin-1 beta, interleukin-1 receptor antagonist, and soluble interleukin-1 receptor type II secretion in chronic fatigue syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

A psychiatric study of nonorganic chronic headache patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

Annual review prize lecture cytokines - killers in the brain?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

Abnormalities of indoleamines in affective disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

A critical appraisal of X-linked bipolar illness. Evidence for the assumed mode of inheritance is lacking

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

The thyroid and melancholia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

Learned helplessness in humans: critique and reformulation

21 January 2018

2 references

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

21 January 2018

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

7 January 2021

Magnitude of stress-induced brain norepinephrine depletion varies with age

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

Alterations in brain norepinephrine metabolism induced by environmental stimuli previously paired with inescapable shock.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

High-speed chronoamperometric measurements of mesolimbic and nigrostriatal dopamine release associated with repeated daily stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

Differential effects of inescapable footshocks and of stimuli previously paired with inescapable footshocks on dopamine turnover in cortical and limbic areas of the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

Stress and the mesocorticolimbic dopamine systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

Enhanced tyrosine hydroxylation in hippocampus of chronically stressed rats upon exposure to a novel stressor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

Central cyclic-AMP-linked noradrenergic receptors: new findings on properties as related to the actions of stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

Effect of chronic variable stress on monoamine receptors: influence of imipramine administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

Induction of corticotropin-releasing hormone gene expression by glucocorticoids: implication for understanding the states of fear and anxiety and allostatic load.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

Chronic depressions*Part 2. Sleep EEG differentiation of primary dysthymic disorders from anxious depressions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

Subthreshold depressions: clinical and polysomnographic validation of dysthymic, residual and masked forms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

EEG sleep characteristics in dysthymia and major depressive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

Natural history and preventative treatment of recurrent mood disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

Treatment outcome validation of DSM-III depressive subtypes. Clinical usefulness in outpatients with mild to moderate depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

Acute response of social functioning in dysthymic patients with desipramine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

Desipramine for the treatment of "pure" dysthymia versus "double" depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

Double-blind study of imipramine versus phenelzine in Melancholias and Dysthymic Disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

A placebo-controlled, randomized clinical trial comparing sertraline and imipramine for the treatment of dysthymia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

5-HT2 receptor antagonism in dysthymic disorder: a double-blind placebo-controlled study with ritanserin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

The Nottingham study of neurotic disorder: comparison of drug and psychological treatments.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

Conceptualization and measurement of quality of life in dementia: the dementia quality of life instrument (DQoL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

Maintenance therapy for chronic depression. A controlled clinical trial of desipramine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

The influence of alprazolam on the monoaminergic neurotransmitter systems in dysthymic patients. Relationship to clinical response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

Amisulpride versus fluoxetine in patients with dysthymia or major depression in partial remission: a double-blind, comparative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

Dehydroepiandrosterone treatment of midlife dysthymia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

Treatment of refractory chronic depression and dysthymia with high-dose thyroxine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

Role of the dopaminergic system in depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

Treatment of chronic depression with sulpiride: evidence of efficacy in placebo-controlled single case studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

Psychiatric disorders in relatives of probands with panic disorder and/or major depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

The role of methylphenidate in psychiatry

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

Understanding the comorbidity between early-onset dysthymia and cluster B personality disorders: a family study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

Diathesis-stress theories in the context of life stress research: implications for the depressive disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

Coping theory and research: past, present, and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

Primary dysthymia: a study of several psychosocial, endocrine and immune correlates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

Stressful life events and coping styles in relation to dysthymia and major depressive disorder: variations associated with alleviation of symptoms following pharmacotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

Double-blind comparison of sertraline, imipramine, and placebo in the treatment of dysthymia: psychosocial outcomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

Psychosocial characteristics of adolescents with a past history of dysthymic disorder: comparison with adolescents with past histories of major depressive and non-affective disorders, and never mentally ill controls.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

21 January 2018

Scaling of Life Events

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

Evidence for an immune response in major depression: a review and hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2 and transferrin receptor in major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

Psychoneuroimmunology and the cytokine action in the CNS: implications for psychiatric disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

Increased soluble interleukin-2 receptor concentrations in suicide attempters.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

The macrophage theory of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

Corticotropin releasing hormone in the pathophysiology of melancholic and atypical depression and in the mechanism of action of antidepressant drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

Effect of peripheral and central cytokines on the hypothalamic-pituitary-adrenal axis of the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

Major depression and activation of the inflammatory response system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

Differential effects of neuropeptides on cytokine production by mouse helper T cell subsets.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

The neuropsychiatric effects of treatment with interleukin-2 and lymphokine-activated killer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

Mood and cognitive disorders in cancer patients receiving cytokine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

Transduction of psychosocial stress into the neurobiology of recurrent affective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

Anhedonic and anxiogenic effects of cytokine exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

Feedback action and tonic influence of corticosteroids on brain function: a concept arising from the heterogeneity of brain receptor systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

Glucocorticoids and the genesis of depressive illness. A psychobiological model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

Plasma corticotropin-releasing factor in depressive disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

Phenotypic plasticity of CRF neurons during stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

Interleukin-1-induced plasticity of hypothalamic CRH neurons and long-term stress hyperresponsiveness.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

Psychiatric implications of basic and clinical studies with corticotropin-releasing factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

The syntax of immune-neuroendocrine communication

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

Neurocircuitry of stress: central control of the hypothalamo-pituitary-adrenocortical axis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

Influence of interleukin-1beta on exploratory behaviors, plasma ACTH, corticosterone, and central biogenic amines in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

Variations of nucleus accumbens dopamine and serotonin following systemic interleukin-1, interleukin-2 or interleukin-6 treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

Sickness behavior as a new target for drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

Do early-life events permanently alter behavioral and hormonal responses to stressors?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

Early environmental regulation of forebrain glucocorticoid receptor gene expression: implications for adrenocortical responses to stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

A Registry-Based Twin Study of Depression in Men

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

Results of the DSM-IV mood disorders field trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

7 January 2021

Pharmacotherapy of Dysthymia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

7 January 2021

The clinical spectrum of so-called "minor" depressions

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

7 January 2021

Cognitive therapy versus fluoxetine in the treatment of dysthymic disorder

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

7 January 2021

"Double depression": two-year follow-up

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

7 January 2021

Does the chronological relationship between the onset of dysthymia and major depression influence subsequent response to antidepressants?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

7 January 2021

Prevalence of anxiety disorders comorbidity in bipolar depression, unipolar depression and dysthymia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

7 January 2021

Does a coexisting anxiety disorder predict persistence of depressive illness in primary care patients with major depression?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

7 January 2021

DSM-III-R axis II comorbidity in dysthymia and major depression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

7 January 2021

Early- versus late-onset dysthymic disorder: comparison in out-patients with superimposed major depressive episodes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

7 January 2021

Depressive personality: associations with DSM-III-R mood and personality disorders and negative and positive affectivity, 30-month stability, and prediction of course of Axis I depressive disorders.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

7 January 2021

Comorbid dysthymia and substance disorder: treatment history and cost

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

7 January 2021

Psychosocial characteristics of "double depression"

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

7 January 2021

Chronic depressions. Part 1. Clinical and familial characteristics in 137 probands

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

7 January 2021

Endocrine and cytokine correlates of major depression and dysthymia with typical or atypical features

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

7 January 2021

Altered cytokine release in peripheral blood mononuclear cell cultures from patients with the chronic fatigue syndrome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

7 January 2021

Comorbidity of headache and depressive disorders

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

7 January 2021

Psychiatric comorbidity and psychosocial stress in patients with tension-type headache from headache centers in Italy. The Italian Collaborative Group for the Study of Psychopathological Factors in Primary Headaches

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

7 January 2021

Biogenic amines and depression. Biochemical and pharmacological separation of two types of depression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

7 January 2021

Personal vulnerability, life events, and depressive symptoms: A test of a specific interactional model

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

7 January 2021

Illusion of control: invulnerability to negative affect and depressive symptoms after laboratory and natural stressors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

7 January 2021

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

7 January 2021

Catecholamine depletion in mice upon reexposure to stress: Mediation of the escape deficits produced by inescapable shock

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

7 January 2021

Prior exposure to chronic stress results in enhanced synthesis and release of hippocampal norepinephrine in response to a novel stressor.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

7 January 2021

The determinants of stress-induced activation of the prefrontal cortical dopamine system

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

7 January 2021

Repeated stress increases locomotor response to amphetamine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

7 January 2021

Chronic stressors and depression: distinguishing characteristics and individual profiles

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

7 January 2021

Primary early onset dysthymia, biochemical correlates of the therapeutic response to fluoxetine: I. Platelet monoamine oxidase and the dexamethasone suppression test

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

7 January 2021

The role of psychosocial and biological variables in separating chronic and non-chronic major depression and early-late-onset dysthymia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

7 January 2021

Moclobemide and imipramine in chronic depression (dysthymia): an international double-blind, placebo-controlled trial. International Collaborative Study Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

7 January 2021

Plasma neurotransmitters, blood pressure, and heart rate during supine resting, orthostasis, and moderate exercise in dysthymic depressed patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

7 January 2021

Clinical symptoms and platelet monoamine oxidase in subgroups and different states of affective disorders

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

7 January 2021

Primary early onset dysthymia, biochemical correlates of the therapeutic response to fluoxetine: II. Urinary metabolites of serotonin, norepinephrine, epinephrine and melatonin

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

7 January 2021

A dual-task analysis of resource allocation in dysthymia and anhedonia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

7 January 2021

Early stimulus processing in dysthymia and anhedonia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

7 January 2021

Characterological depressions. Clinical and sleep EEG findings separating 'subaffective dysthymias' from 'character spectrum disorders'

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

7 January 2021

Treatment of dysthymic disorder

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

7 January 2021

Sildenafil for iatrogenic serotonergic antidepressant medication-induced sexual dysfunction in 4 patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

7 January 2021

Dysthymic disorder: a comparison of DSM-IV and ICD-10 and issues in differential diagnosis.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

7 January 2021

The treatment of chronic depression, part 2: a double-blind, randomized trial of sertraline and imipramine.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

7 January 2021

Imipramine treatment for chronic depression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

7 January 2021

Studies of reversible and selective inhibitors of monoamine oxidase A in dysthymia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

7 January 2021

A randomized double-blind study of fluoxetine versus placebo in the treatment of dysthymia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

7 January 2021

Controlled efficacy study of fluoxetine in dysthymia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

7 January 2021

Venlafaxine in dysthymic disorder

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

7 January 2021

Relevance of DMS-III depressive subtype and chronicity of antidepressant efficacy in atypical depression. Differential response to phenelzine, imipramine, and placebo

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

7 January 2021

Amisulpride versus imipramine and placebo in dysthymia and major depression. Amisulpride Study Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

7 January 2021

Amisulpride versus amineptine and placebo for the treatment of dysthymia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

7 January 2021

Therapeutic efficacy of specific serotonin reuptake inhibitors (SSRIs) in dysthymia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

7 January 2021

Predictors of response to desipramine in dysthymia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

7 January 2021

Chromium potentiation of antidepressant pharmacotherapy for dysthymic disorder in 5 patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

7 January 2021

Follow-up assessment of medication-treated dysthymia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

7 January 2021

Family study of early-onset dysthymia. Mood and personality disorders in relatives of outpatients with dysthymia and episodic major depression and normal controls

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

7 January 2021

Comorbidity between dysthymic and major depressive disorders: A family study analysis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

7 January 2021

Low activity allele of catechol-o-methyltransferase gene and Japanese unipolar depression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

7 January 2021

Types of stressful life event and the onset of anxiety and depressive disorders

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

7 January 2021

Generation of stress in the course of unipolar depression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

7 January 2021

Stressful life events preceding the onset of neurotic depression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

7 January 2021

Life events and the endogenous-nonendogenous distinction in the treatment and posttreatment course of depression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

7 January 2021

Chronic stress and depressive disorders in older adults

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

7 January 2021

The functioning and well-being of depressed patients. Results from the Medical Outcomes Study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

7 January 2021

Impairment of work and leisure in depressed outpatients. A preliminary communication

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

7 January 2021

Historical and nosological aspects of dysthymia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

7 January 2021

Social adjustment in dysthymia, double depression and episodic major depression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

7 January 2021

Interpersonal improvement in chronically depressed patients treated with desipramine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

7 January 2021

Life satisfaction and psychosocial functioning in chronic depression: effect of acute treatment with antidepressants

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

7 January 2021

The treatment of chronic depression, part 3: psychosocial functioning before and after treatment with sertraline or imipramine.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

7 January 2021

Remission and relapse in major depression: a two-year prospective follow-up study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

7 January 2021

Interleukin-1 beta: a putative mediator of HPA axis hyperactivity in major depression?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

7 January 2021

Evidence for a systemic immune activation during depression: results of leukocyte enumeration by flow cytometry in conjunction with monoclonal antibody staining

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

7 January 2021

Changes in immunoglobulin, complement and acute phase protein levels in the depressed patients and normal controls

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

7 January 2021

Interleukin-6 serum levels in depressed patients before and after treatment with fluoxetine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

7 January 2021

Lymphocyte subsets associated with major depression and dysthymia: modification by antidepressant treatment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

7 January 2021

Life events and depression. Part 2. Results in diagnostic subgroups, and in relation to the recurrence of depression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

7 January 2021

Aversive and appetitive events evoke the release of corticotropin-releasing hormone and bombesin-like peptides at the central nucleus of the amygdala.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

7 January 2021

Dopamine transmission in the initiation and expression of drug- and stress-induced sensitization of motor activity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

7 January 2021

Low plasma cortisol in bulimia nervosa patients with reversed neurovegetative symptoms of depression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

7 January 2021

Interleukin-1-induced long-lasting changes in hypothalamic corticotropin-releasing hormone (CRH)--neurons and hyperresponsiveness of the hypothalamus-pituitary-adrenal axis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

7 January 2021

CSF corticotropin-releasing hormone and somatostatin in major depression: response to antidepressant treatment and relapse

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

7 January 2021

Effect of bacterial endotoxin and interleukin-1 beta on hippocampal serotonergic neurotransmission, behavioral activity, and free corticosterone levels: an in vivo microdialysis study.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000697

7 January 2021

Pituitary control of immune cells

1 reference

27 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/SJ.MP.4000697

Learned helplessness as a model of depression. Comment and integration

1 reference

27 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/SJ.MP.4000697

Identifiers

DOI

10.1038/SJ.MP.4000697

1 reference

30 July 2017

1 reference